Protalix BioTherapeutics, Inc.
PLX
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipelā¦ read more
Healthcare
Biotechnology
27 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$1.86
Price-3.63%
-$0.07
1Y
Price
Market Cap
$148.302m
Small
Price/Earnings 3y Avg5y Avg
20.7x
Premium
Premium
Financials Overview
Key metrics over the past few years+11.5%
EBITDA Margin+1.1%
Net Profit Margin-36.2%
Free Cash Flow MarginRevenue
$61.948m
+16.0%
1y CAGR+11.7%
3y CAGR+14.8%
5y CAGREarnings
$6.275m
+114.0%
1y CAGR+68.3%
3y CAGR+62.7%
5y CAGREPS
$0.07
+75.0%
1y CAGR+49.1%
3y CAGR+49.3%
5y CAGRBook Value
$49.903m
$78.486m
Assets$28.583m
Liabilities$5.349m
DebtDebt to Assets
6.8%
0.5x
Debt to EBITDAFree Cash Flow
-$3.444m
-146.6%
1y CAGR+114.5%
3y CAGR+56.3%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company